Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics
Restricted accessOtherFirst published online September, 2007
Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics
Hyperprolactinaemia is a common finding in patients treated with antipsychotics. A complete cohort of 194 schizophrenia and bipolar disorder patients receiving antipsychotics in a single community mental health trust in Halifax UK underwent routine prolactin screening in the absence of any reLevant symptomatoLogy. Values above the upper limit of normal were measured in 38% of the cohort and were more common in females (52%) than males (26%). Significantly elevated levels (>1000 mIU/l) were measured in 21% of the cohort. Risperidone monotherapy treatment was associated with hyperprolactinaemia in 69% of patients ( n = 35) and in 100% of female patients (n = 16) and amisulpride monotherapy in 100% (n = 7). Prolactin screening is not currently undertaken routinely in the UK. These data give some indication of prevalence of varying degrees of hyperproLactinaemia that might be found when screening an asymptomatic cohort of schizophrenia and bipolar outpatients. Clinicians may be helped by the reporting of such categorical data from clinical trials in addition to mean cohort values of prolactin. Long-term hyperprolactinaemia may be associated with clinical sequeLae in some patients.
Becker D. , Liver O. , Mester M. , Rapoport M. , Weizman A. , Weiss M. (2003) Risperidone but not olanzapine decreases bone mineral density in female premenopausal schizophrenia patients . J Clin Psychol64: 761—766
2.
Bitter I. , Basson B. , Dossenbach M. (2005) Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients . Int Clin Psychopharmacol20: 19—21
3.
Chue P. , Eerdekens M. , Augustyns I. , Lachaux B. , Molcan P. , Eriksson L. , Pretorius H. , David AS (2005) Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets . Eur Neuropsychopharmacol15: 111—117
4.
Crawford A.M. , Beasley C.M. , Tollefson G.D. (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations . Schizophr Res26: 41—54
5.
Crockett A. , Goldstein M. , Bushe C. (2005) How has NICE guidelines affected prescribing in depot clinic schizophrenia outpatients? The Dewsbury experience. British Association ofPsychopharmacology2005 Summer Meeting, Harrogate, UK, 24—27 July 2005
6.
David S. , Taylor C. , Kinon B. , Brier A. (2000) The effects of olanzapine, risperidone and haloperidol on plasma prolactin levels in patients with schizophrenia . Clin Ther22: 1085—1096
7.
Foss M.C. , Paula F. , Paccola G. , Piccinato C. (1995) Peripheral glucose metabolism in human hyperprolactinaemia . Clin Endocrinol43: 721—726
8.
Grunder G. , Wetzel H. , Schloesser R. , Anghelescu I. , Hillert A. , Lange K. et al. (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender . Biol Psychiatry45: 89—97
9.
Haddad P. , Wieck A. (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management . Drugs64(20): 2291—2314
10.
Halbreich U. , Kinon BJ , Gilmore JA , Kahn LS ( 2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects . Psychoneuroendocrinology28(Suppl. 1): 53—67
11.
Hummer M. , Malik P. , Gasser R. , Hofer A. , Kemmler G. , Naveda R. , Rettenbacher M. , Fleischacker W. (2005) Osteoporosis in patients with schizophrenia . Am J Psychiatry162: 162—167
12.
Kinon B.J. , Gilmore J. , Liu H. , Halbreich U.M. (2003a) Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone . Psychoneuroendocrinology28: 55—68
13.
Kinon B. , Gilmore J. , Liu H. , Halbreich U. (2003b) Hyperprolactinaemia in response to antipsychotic drugs: characterisation across comparative clinical trials . Psychoneuroendocrinology28: 69—82
14.
Kleinberg D.L. , Davis J.M. , De Coster R. (1999) Prolactin levels and adverse effects in patients treated with risperidone . J Clin Psychopharmacol19: 57—61
15.
Kuruvilla A. , Peedicayil J. , Srikrishna G. , Kuruvilla K. , Kanagasabapathy A.S. (1992) A study of serum prolactin levels in schizophrenia; comparison of males and females . Clin Exp Pharmacol Physiol19: 603—606
16.
Lehman A F. , Lieberman J A. , Dixon L B. , McGlashan T H. , Miller A L. , Perkins D O. , Kreyenbuhl J. ; American Psychiatric Association; Steering Committee on Practice Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia, second edition . Am J Psychiatry161(Suppl. 2): 1—56
17.
Lieberman J A. , Stroup T S. , McEvoy J P. , Swartz M S. , Rosenheck R A. , Perkins D O. et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia . N Engl J Med353(12): 1209—1223
18.
Meaney A.M. , O'Keane V. (2003) Reduced bone mineral density in patients with schizophrenia receiving prolactin raising antipsychotic medication . J Psychopharmacol17: 455—458
19.
Meaney A.M. , Smith S. , Howes O.D. , O'Brien M. , Murray R.M. , O'Keane V. (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia . Br J Psychiatry184: 503—508
20.
Montgomery J. , Winterbottom E. , Jessani M. , Kohegyi E. , Fulmer J. , Seamonds B. , Josiassen R.C. (2004) Prevalence of hyperprolactinaemia in schizophrenia: association with typical and atypical antipsychotic treatment . J Clin Psychiatry65: 1491—1498
21.
O'Keane V. , Meaney A.M. (2005) Antipsychotic drugs. A new risk factor for osteoporosis in young women with schizophrenia?J Clin Psychopharmacol25: 26—31
22.
Purdon S.E. , Jones B.D. , Stip E. , Labelle A. , Addington D. , David S.R. et al. (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol . Arch Gen Psychiatry57: 249—258
23.
Royal College of Physicians (1999) Osteoporosis: clinical guidelines for prevention and treatment. Royal College of Physicians, London
24.
Schernthaner C. , Prager R. , Punzengruber C. , Luger A. (1985) Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo . Diabetologia28: 138—142
25.
Smith S.M. , O'Keane V. , Murray R. (2002a) Sexual dysfunction in patients taking conventional antipsychotic medication . Br J Psychiatry181: 49—55
26.
Smith S. , Wheeler M J, Murray (2002b) The effects of antipsychotic induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis . J Clin Psychopharmacol22: 109—114
27.
Tollefson G.D. , Beasley C.M. , Tran P.V. , Street J.S. , Krueger J.A. , Tamura R.N. et al. (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial . Am J Psychiatry154: 457—465
28.
Tran P.V. , Hamilton S.H. , Kuntz A.J. , Potvin J.H. , Andersen S.W. , Beasley C. Jr , Tollefson G.D. (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders . J Clin Psychopharmacol17: 407—418
29.
Wang P.S. , Walker A.M. , Tsuang M.T. (2002) Dopamine antagonists and the development of breast cancer . Arch Gen Psychiatry59: 1147—1154
30.
Wieck A. , Haddad P. (2002) Hyperprolactinaemia caused by antipsychotic drugs . BMJ324: 250—252
31.
Wieck A. , Haddad P. (2003) Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences . Br J Psychol182: 199—204
32.
Windgassen K. , Wesselman U. , Schulze Monking H (1996) Galactorrhoea and hyperprolactinaemia in schizophrenic patients on neuroleptics: frequency and aetiology . Neuropsychobiology33: 142—146
33.
Zhong K.X. , Sweitzer D.E. , Hamer R.M. , Lieberman J.A. (2006) Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study . J Clin Psychiatry67: 1093—1103
